![Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha](https://static.seekingalpha.com/uploads/sa_presentations/142/55142/slides/10.jpg?1588853570)
Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha
![Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha](https://static1.seekingalpha.com/uploads/sa_presentations/142/55142/slides/20.jpg?1588853570)
Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha
![Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha](https://static1.seekingalpha.com/uploads/sa_presentations/142/55142/slides/31.jpg?1588853570)
Teva Pharmaceutical Industries Limited 2020 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha
![Teva still suffers from negative revenue growth and return to growth is still distant - MidgardFinance.com Teva still suffers from negative revenue growth and return to growth is still distant - MidgardFinance.com](https://www.midgardfinance.com/companies/T/TEVA/TEVA2019Q1_slide08.png)
Teva still suffers from negative revenue growth and return to growth is still distant - MidgardFinance.com
![$41B for Allergan's generics business? Investors now say Teva 'grossly' overpaid: FT | Fierce Pharma $41B for Allergan's generics business? Investors now say Teva 'grossly' overpaid: FT | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/2016-06/teva1.jpg?VersionId=TdxPbPad17K4AdNXBhnNKb718L2n4FzW)
$41B for Allergan's generics business? Investors now say Teva 'grossly' overpaid: FT | Fierce Pharma
![Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg](http://reorg-research.com/images/Teva+Org+Chart.png)